If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
36、for women with ER-positive or PR-positive breast cancer(激素疗法对ER阳性或PR阳性乳腺癌十分有效). These are cancers that grow more rapidly in response to the hormones estrogen or progesterone(即指对雌激素和孕酮的反应具有生长加速作用的乳腺肿瘤). Hormone therapy can block this effect(激素疗法...
In this report, we present the case of a female patient with relapsed and metastatic breast cancer, whose histology transformed from initially triplenegative to Luminal-B type (HER2 positive) (i.e., ER, PR, and HER2 positive). She underwent systematic chemotherapy, tar...
使用950例病例进行边缘状态的单变量生存模型显示,阳性边缘与PFI(p < 0.001)和OS(p = 0.006)作为终点的生存率显著相关(图1)。除了边缘状态外,分期、TNM、PAM50亚型和激素受体(雌激素受体(ER)、孕激素受体(PR))状态与疾病进展显著相关(表3)。在对组织学进行生存模型分析时,发现粘液性癌与导管癌相比具有显著的生...
Breast cancer is a heterogeneous disease, and within the HER-2 positive subtype this is highly exemplified by the presence of substantial phenotypical and clinical heterogeneity, mostly related to hormonal receptor (HR) expression. It is well known how HER-2 positivity is commonly associated with ...
A cancer cell positive for the ER and/or PR is termed hormone-receptor positive (HR+). Identifying the hormone receptor status, often using immunohistochemistry, of a breast cancer sample is crucial in treating it. For instance, an ER+ breast cancer patient may be administered hormone therapy ...
Get information on breast cancer symptoms, rash, awareness, lump, stages, treatment, causes, and screening. Around 40,000 women in the U.S. die of breast cancer each year. Read about different tests, prevention and early signs.
Estrogen receptor (ER)-positive breast cancer represents approximately 70% of all breast cancers and the selec- tive ER modulator (SERM), tamoxifen, remains the mainstay of treatment in pre-menopausal women [1]. Although several studies have established the role of tamoxifen in significantly reduc...
ER+/HER2- breast cancer is a common subtype of breast cancer. This study aimed to evaluate the prognostic value of ER-to-PR difference (EPD) in ER+/HER2- early breast cancer (EBC). A retrospective cohort study was conducted, including 3,340 ER+/HER2- EBC
All of the patients had prior ER positive breast cancer treated with surgery, chemotherapy, radiation, and anti-estrogen endocrine therapy. Two patients had known internal mammary nodes (IMNs) at the time of diagnosis. These were not included in the primary radiation fields, and in one patient...